Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies (MK-4280-003)

Trial Identifier: 4280-003
Sponsor: MSD
Start Date: October 2018
Primary Completion Date: October 2028
Study Completion Date: October 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English

Trial Locations

Country Location
Australia, New South Wales Concord, New South Wales, Australia, 2139
Australia, Queensland Woollongabba, Queensland, Australia, 4102
Australia, Victoria Clayton, Victoria, Australia, 3168
Australia, Victoria Fitzroy, Victoria, Australia, 3065
Canada, BC Vancouver, BC, Canada, V5Z 1L3
Canada, MB Winnipeg, MB, Canada, R3E 0V9
Canada, ON Toronto, ON, Canada, M5G 2M9
Canada, QC Montreal, QC, Canada, H3T 1E2
Germany, Nordrhein-Westfalen Koeln, Nordrhein-Westfalen, Germany, 50937
Germany, Sachsen Leipzig, Sachsen, Germany, 4103
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Jerusalem, N/A, Israel, 9112001
Israel, N/A Ramat Gan, N/A, Israel, 5262001
Israel, N/A Tel Aviv, N/A, Israel, 6423906
Italy, Emilia-Romagna Bologna, Emilia-Romagna, Italy, 40138
Italy, Forli-Cesena Meldola, Forli-Cesena, Italy, 47014
Italy, Milano Rozzano, Milano, Italy, 20089
United States, AZ Gilbert, AZ, United States, 85234
United States, CA Duarte, CA, United States, 91010
United States, CA Los Angeles, CA, United States, 90095
United States, CA Monterey, CA, United States, 93940
United States, CA San Francisco, CA, United States, 94143
United States, MA Boston, MA, United States, 02215
United States, PA Philadelphia, PA, United States, 19111
United States, TX Austin, TX, United States, 78705